Form 4: Centessa Officer's Equity Changes Reported

Centessa Pharmaceuticals' Chief Technology & Quality Officer, Tia L. Bush, reported recent equity transactions including RSU grants and option awards.

Summary

• Tia L. Bush, Chief Technology & Quality Officer of Centessa Pharmaceuticals plc, reported transactions involving the company's Ordinary Shares and derivative securities.
• On February 1, 2026, 8,549 Ordinary Shares were disposed of at a price of $24.57 per share to cover tax withholding obligations related to the vesting of restricted share units.
• On February 2, 2026, 35,000 Restricted Share Units (RSUs) were acquired. These RSUs will vest in four equal annual installments, with the first vesting on February 2, 2027.
• Also on February 2, 2026, 140,000 Share Options were acquired with an exercise price of $25.19. These options will vest in 48 equal monthly installments, with the first installment vesting on March 2, 2026, and have an expiration date of February 2, 2036.
• Following these transactions, Tia L. Bush beneficially owns 147,954 Ordinary Shares directly and 140,000 derivative Share Options directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily because it signifies continued executive incentive and alignment with shareholder interests through new equity awards, despite the routine tax-related share disposition.

Positives

• The acquisition of 35,000 Restricted Share Units (RSUs) aligns the Chief Technology & Quality Officer's long-term interests with those of shareholders.
• The award of 140,000 Share Options provides a significant incentive for future performance and value creation for the company.
• The increase in beneficial ownership of Ordinary Shares to 147,954 demonstrates continued commitment from a key executive.

Negatives

• A disposition of 8,549 Ordinary Shares occurred to cover tax withholding obligations, which, while routine for RSU vesting, represents a reduction in direct shareholding.

Future Outlook

na

Industry Context

StockSavvy.ai notes that this Form 4 filing details routine executive compensation and insider transactions, which are common occurrences in publicly traded biotechnology and pharmaceutical companies. These transactions reflect the company's ongoing efforts to incentivize and retain key management personnel through equity awards, aligning their interests with long-term shareholder value.

Comparison to Industry Standards

• The structure of equity compensation, including Restricted Share Units (RSUs) and stock options with multi-year vesting schedules, is a standard practice across the biotechnology and pharmaceutical industry for executive retention and motivation.
• The disposition of shares to cover tax withholding obligations upon RSU vesting is a typical and expected event for equity compensation in the U.S. market, consistent with practices at comparable companies like Moderna (MRNA) or BioNTech (BNTX) for their executives.

Stakeholder Impact

• Shareholders: Increased alignment of a key executive's financial interests with the company's long-term performance through equity awards.
• Employees: Reflects the company's compensation strategy for executives, potentially influencing broader compensation practices.

Next Steps

• The 35,000 Restricted Share Units will begin vesting in four equal annual installments starting February 2, 2027.
• The 140,000 Share Options will begin vesting in 48 equal monthly installments starting March 2, 2026.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation and insider transactions, which do not provide new fundamental information to warrant a change in investment recommendation. The transactions reflect standard practices for incentivizing management and do not indicate any significant shift in the company's operational or financial outlook.

Keywords

Centessa Pharmaceuticals, CNTA, Form 4, Insider Transaction, Restricted Share Units, Stock Options, Equity Compensation, Executive Compensation